Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM230 plus PD-1 inhibitor in HER2-related solid tumors
CTR20262872Phase 2Active
- Sponsor
- BioMinds
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BM230 in Nonhematologic neoplasms, microsatellite instability-high cancer, Esophageal Squamous Cell Carcinoma (ESCC), transitional cell carcinoma (TCC), cholangiocarcinoma (CCA), sponsored by BioMinds. Started Aug 2026; status: active.
02
Drugs
BM230
03
Conditions
Nonhematologic neoplasmsmicrosatellite instability-high cancerEsophageal Squamous Cell Carcinoma (ESCC)transitional cell carcinoma (TCC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on CTR20262872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262872.